Boryung Pharma to commercialize Aplidin from Spain

21:05
What you need to know about Adani's US bribery indictment
18:07
Hyundai Motor’s Genesis US push challenged by Trump’s tariff hike: sources
18:04
Oasis confirms first Korean concert in 16 years
17:55
North Korean leader ‘convinced’ dialogue won’t change US hostility
17:54
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
17:47
Naver Webtoon promises creative freedom, responsible webtoon platform
17:41
Two jailed for forcing disabled teens into prostitution
17:39
Japan confirms vice-ministerial level figure attending Sado mine memorial
17:17
Daewoo E&C chair honored in India for boosting bilateral economic ties
17:16
South Korean military plans to launch new division for future warfare

Boryung Pharma to commercialize Aplidin from Spain

Oct. 4, 2016 - 14:14 By 윤정현

[DISCLOSURE] Boryung Pharmaceutical (003850) reported on Oct. 4 that it has signed a technology introduction contract with PharmaMar of Spain for rights to launch and commercialize Aplidin, a treatment option for multiple myeloma, in Korea.

By Yun Jeong-hyeon (clareyun@heraldcorp.com)

윤정현